Literature DB >> 2156497

Effects of a single cleavage in insulin-like growth factors I and II on binding to receptors, carrier proteins and antibodies.

J Jansen1, S C van Buul-Offers, C M Hoogerbrugge, J L Van Den Brande.   

Abstract

Two somatomedin-like peptides were extracted from Cohn fraction IV of human plasma and brought to homogeneity: one focused at pH 7.8 and the other at pH less than 5.6. Each consisted of two peptide chains interlinked by disulphide bonds. The basic peptide was identical to insulin-like growth factor I (IGF-I) and had a single cleavage in the C-domain before Arg37 [IGF-I(Arg36cl)]. The acid peptide showed identity with IGF-II, with a cleavage in the B-domain before Arg30 [IGF-II(Ser29cl)]. The effects of these cleavages on the characteristics of binding to type I and type II receptor sites, to binding proteins and to antibodies was studied. Binding of IGF-I(Arg36cl) to antibodies directed against the B-domain or against the AD-domain of IGF-I was the same as IGF-I binding. Thus the cleavage does not influence these antigenic sites. In contrast, binding of IGF-I(Arg36cl) to the type I receptor on human and bovine placental cell membranes was markedly decreased compared with IGF-I binding. Binding to the insulin receptor on human placental cell membranes was slightly diminished, whereas the interaction with specific type II receptors on bovine placental cell membranes was unaffected. There was only a minor influence of the cleavage on the region involved in binding to binding proteins. The cleavage in IGF-II(Ser29cl) diminished binding to antibodies directed against the C-domain of IGF-II, compared with binding of IGF-II itself. Binding to receptors (type I and type II) was changed less profoundly. With 125I-labelled IGF-II(Ser29cl), less insulin was needed in order to obtain 50% displacement of the tracer compared with displacement of 125I-labelled IGF-II. The cleaved form of IGF-II probably has a greater affinity towards the common receptor population than does native IGF-II. Binding to binding proteins was not affected by the cleavage in IGF-II.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156497      PMCID: PMC1131162          DOI: 10.1042/bj2660513

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

Review 1.  Biological and immunological properties of insulin-like growth factors (IGF) I and II.

Authors:  J Zapf; C Schmid; E R Froesch
Journal:  Clin Endocrinol Metab       Date:  1984-03

2.  Degradation of somatomedins by the thioredoxin system.

Authors:  G Enberg; A Holmgren
Journal:  FEBS Lett       Date:  1985-04-08       Impact factor: 4.124

3.  Tertiary structures, receptor binding, and antigenicity of insulinlike growth factors.

Authors:  T L Blundell; S Bedarkar; R E Humbel
Journal:  Fed Proc       Date:  1983-06

4.  IGF-II binding on human lymphoid cells: demonstration of a common high affinity receptor for insulin like peptides.

Authors:  R L Hintz; A V Thorsson; G Enberg; K Hall
Journal:  Biochem Biophys Res Commun       Date:  1984-02-14       Impact factor: 3.575

5.  Synthesis and characterization of molecular hybrids of insulin and insulin-like growth factor I. The role of the A-chain extension peptide.

Authors:  G L King; C R Kahn; B Samuels; W Danho; E E Bullesbach; H G Gattner
Journal:  J Biol Chem       Date:  1982-09-25       Impact factor: 5.157

6.  The effect of different isolation procedures on the yields of insulin-like growth factors from human plasma.

Authors:  H J Cornell
Journal:  Prep Biochem       Date:  1982

7.  Insulin-like growth factor: a model for tertiary structure accounting for immunoreactivity and receptor binding.

Authors:  T L Blundell; S Bedarkar; E Rinderknecht; R E Humbel
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

8.  Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor.

Authors:  M A Cascieri; G G Chicchi; J Applebaum; N S Hayes; B G Green; M L Bayne
Journal:  Biochemistry       Date:  1988-05-03       Impact factor: 3.162

9.  Growth-stimulating effects of somatomedin-/insulin-like peptides in Snell dwarf mice.

Authors:  S van Buul-Offers; C M Hoogerbrugge; J Branger; M Feijlbrief; J L Van den Brande
Journal:  Horm Res       Date:  1988

10.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; H Walter; E R Froesch
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more
  4 in total

Review 1.  The insulin-like growth factor family of ligands, receptors, and binding proteins.

Authors:  R F Krywicki; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  General overgrowth in the fragile X syndrome: variability in the phenotypic expression of the FMR1 gene mutation.

Authors:  B B de Vries; H Robinson; I Stolte-Dijkstra; C V Tjon Pian Gi; P F Dijkstra; J van Doorn; D J Halley; B A Oostra; G Turner; M F Niermeijer
Journal:  J Med Genet       Date:  1995-10       Impact factor: 6.318

3.  Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues.

Authors:  L T Van der Ven; P J Roholl; T Gloudemans; S C Van Buul-Offers; M J Welters; B A Bladergroen; J A Faber; J S Sussenbach; W Den Otter
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Histamine-stimulated expression of insulin-like growth factors in human glioma cells.

Authors:  L T Van der Ven; S C Van Buul-Offers; T Gloudemans; P J Roholl; J S Sussenbach; W Den Otter
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.